Grifols acquires 40% stake in VCN Bioscience - MarketLine Financial Deals

Grifols acquires 40% stake in VCN Bioscience

Grifols acquires 40% stake in VCN Bioscience - MarketLine Financial Deals
Grifols acquires 40% stake in VCN Bioscience
Published Jul 09, 2012
2 pages — Published Jul 09, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Grifols, S.A., a pharmaceutical and chemical company, has acquired a 40% stake in VCN Biosciences, a developer of new therapeutic approaches for tumors that lack effective treatment.

  
Source:
Document ID
MA116783_120717
Country
Ticker
GRF=ES
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Grifols acquires 40% stake in VCN Bioscience" Jul 09, 2012. Alacra Store. Dec 04, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Grifols-acquires-40-stake-in-VCN-Bioscience-2052-84339>
  
APA:
MarketLine Financial Deals. (2012). Grifols acquires 40% stake in VCN Bioscience Jul 09, 2012. New York, NY: Alacra Store. Retrieved Dec 04, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Grifols-acquires-40-stake-in-VCN-Bioscience-2052-84339>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.